Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 3:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Major Depressive Disorder
Interventions
vilazodone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
38
States / cities
Garden Grove, California • San Diego, California • Torrance, California + 34 more
Conditions
Major Depressive Disorder
Interventions
Placebo, Brexpiprazole, ADT
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more
Conditions
Major Depressive Disorders
Interventions
amibegron (SR58611A), placebo, paroxetine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Major Depressive Disorder
Interventions
Active transcutaneous vagus nerve stimulation, Sham transcutaneous vagus nerve stimulation
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
24 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charlestown, Massachusetts
Conditions
Major Depressive Disorder 1
Interventions
Pharmacogenetic testing
Genetic
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Completed Not applicable Interventional Results available

Genomics Used to Improve DEpression Decisions

NCT02109939
Conditions
Major Depressive Disorder (MDD)
Interventions
GeneSight Psychotropic
Genetic
Lead sponsor
Assurex Health Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
61
States / cities
Birmingham, Alabama • Bellflower, California • Chino, California + 52 more
Conditions
Depressive Disorder
Interventions
Saredutant succinate (SR48968C)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 64 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Healthy Volunteers (Part 1), Major Depressive Disorder (Part 2)
Interventions
HT-2157, Placebo
Drug
Lead sponsor
Dart NeuroScience, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Glendale, California
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Depressive Episode, Major Depressive Disorder
Interventions
Synchronized Transcranial Magnetic Stimulation (sTMS), Sham Stimulation
Device
Lead sponsor
Wave Neuroscience
Industry
Eligibility
22 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 11 more
Not yet recruiting Not applicable Interventional

One-Day cTBS Over the Precuneus

NCT07758010
Conditions
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD), Treatment Resistant Major Depression Disorder
Interventions
Precuneus-targeted continuous theta-burst stimulation, Left dorsolateral prefrontal cortex intermittent theta-burst stimulation, Sham transcranial magnetic stimulation
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Belmont, Massachusetts
Conditions
Pain, Respiratory Depression
Interventions
Hydromorphone, Usual care group
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
60 Years to 90 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Major Depressive Disorder
Interventions
Agomelatine (AGO178C), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Costa Mesa, California • El Centro, California + 39 more
Conditions
Major Depressive Disorder (MDD)
Interventions
Accelerated rTMS treatment
Device
Lead sponsor
NeuroQore Inc.
Industry
Eligibility
22 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
San Jose, California
Conditions
Major Depression Disorder, Depression
Interventions
DMT-Medium Dose, DMT-Low Dose, THC-Medium Dose, THC-Low Dose
Drug
Lead sponsor
Deepak C. D'Souza
Other
Eligibility
21 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Conditions
Depressive Disorder, Major, Hepatitis C
Interventions
Cognitive behavioral treatment for depression
Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Bipolar Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
28
States / cities
Tuscaloosa, Alabama • Little Rock, Arkansas • San Diego, California + 25 more
Conditions
1. Major Depressive Disorder
Interventions
Supplemental TMS, Standard Medication Monotherapy
Device · Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Towson, Maryland
Conditions
Depressive Disorder, Major
Interventions
Brenipatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
32
States / cities
Moorpark, California • Orange, California • New Haven, Connecticut + 29 more
Conditions
Major Depressive Disorder
Interventions
SAGE-217
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
52
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 43 more
Conditions
Major Depressive Disorder
Interventions
SHX-001 Active low dose, Placebo, SHX-001 Active High dose
Drug
Lead sponsor
Shenox Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Gaithersburg, Maryland • Boston, Massachusetts • Dayton, Ohio
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

NCT04711005
Conditions
Major Depressive Disorder
Interventions
(2R,6R)-Hydroxynorketamine hydrochloride, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Depressive Disorder, Major
Interventions
SUVN-911, Placebo
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Completed Phase 2 Interventional Accepts healthy volunteers

Integrated Treatment for Cocaine and Mood Disorders - 1

NCT00227812
Conditions
Cocaine Dependence, Depressive Disorder, Major
Interventions
Bupropion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Houston, Texas
Conditions
Major Depressive Disorder
Interventions
Placebo, Brexpiprazole 1 mg, Brexpiprazole 3 mg
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
65 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
National City, California • Orlando, Florida